These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28939742)

  • 21. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
    Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-neoplastic Fallopian Tube Epithelium Carrying Gene Mutations of a Novel SOX2 Repressor Region is Soil of High-grade Serous Ovarian Cancer.
    Hirohashi Y; Torigoe T
    EBioMedicine; 2016 Aug; 10():17-8. PubMed ID: 27423191
    [No Abstract]   [Full Text] [Related]  

  • 24. WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
    Lee S; Jun J; Kim WJ; Tamayo P; Howell SB
    Anticancer Res; 2020 Nov; 40(11):6017-6028. PubMed ID: 33109540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause.
    Piek JM; Kenemans P; Verheijen RH
    Am J Obstet Gynecol; 2004 Sep; 191(3):718-32. PubMed ID: 15467531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
    J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
    Zhan SJ; Liu B; Linghu H
    Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
    Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
    Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
    Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
    J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.
    Levanon K; Ng V; Piao HY; Zhang Y; Chang MC; Roh MH; Kindelberger DW; Hirsch MS; Crum CP; Marto JA; Drapkin R
    Oncogene; 2010 Feb; 29(8):1103-13. PubMed ID: 19935705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IS "OVARIAN" CANCER A MISNOMER? EXPLORING OVARIAN CANCER ORIGINS IN THE MOUSE.
    Cho KR
    Trans Am Clin Climatol Assoc; 2018; 129():40-47. PubMed ID: 30166697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer.
    Shigeta S; Toyoshima M; Kitatani K; Ishibashi M; Usui T; Yaegashi N
    Oncogene; 2016 Jul; 35(27):3577-86. PubMed ID: 26549031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.
    Lõhmussaar K; Kopper O; Korving J; Begthel H; Vreuls CPH; van Es JH; Clevers H
    Nat Commun; 2020 May; 11(1):2660. PubMed ID: 32461556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
    Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
    Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies.
    Zorn KK; Jazaeri AA; Awtrey CS; Gardner GJ; Mok SC; Boyd J; Birrer MJ
    Clin Cancer Res; 2003 Oct; 9(13):4811-8. PubMed ID: 14581352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.
    George SH; Greenaway J; Milea A; Clary V; Shaw S; Sharma M; Virtanen C; Shaw PA
    J Pathol; 2011 Sep; 225(1):106-17. PubMed ID: 21744340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
    Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
    J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.
    Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ
    Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.
    King ER; Zu Z; Tsang YT; Deavers MT; Malpica A; Mok SC; Gershenson DM; Wong KK
    Gynecol Oncol; 2011 Oct; 123(1):13-8. PubMed ID: 21726895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.